Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Pepgen Inc (PEPG)

Pepgen Inc (PEPG)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.6200 +0.1000 (+6.58%) 04/22/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.6490 +0.0290 (+1.79%) 16:14 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.4700
Day High
1.7800
Open 1.6100
Previous Close 1.5200 1.5200
Volume 385,100 385,100
Avg Vol 275,655 275,655
Stochastic %K 83.92% 83.92%
Weighted Alpha -86.48 -86.48
5-Day Change +0.5200 (+47.27%) +0.5200 (+47.27%)
52-Week Range 0.8801 - 19.2980 0.8801 - 19.2980
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,692
  • Shares Outstanding, K 32,692
  • Annual Sales, $ 0 K
  • Annual Income, $ -89,980 K
  • EBIT $ -98 M
  • EBITDA $ -96 M
  • 60-Month Beta 1.42
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.37

Options Overview Details

View History
  • Implied Volatility 196.40% ( -155.56%)
  • Historical Volatility 141.82%
  • IV Percentile 28%
  • IV Rank 14.80%
  • IV High 1,050.97% on 01/15/25
  • IV Low 47.94% on 01/27/25
  • Put/Call Vol Ratio 2.86
  • Today's Volume 27
  • Volume Avg (30-Day) 44
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 846
  • Open Int (30-Day) 1,466

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.72
  • Number of Estimates 5
  • High Estimate -0.54
  • Low Estimate -0.85
  • Prior Year -0.63
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8801 +84.07%
on 04/09/25
Period Open: 1.7700
1.8400 -11.96%
on 03/24/25
-0.1500 (-8.47%)
since 03/21/25
3-Month
0.8801 +84.07%
on 04/09/25
Period Open: 1.9800
4.4800 -63.84%
on 02/24/25
-0.3600 (-18.18%)
since 01/22/25
52-Week
0.8801 +84.07%
on 04/09/25
Period Open: 11.3900
19.2980 -91.61%
on 07/29/24
-9.7700 (-85.78%)
since 04/22/24

Most Recent Stories

More News
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

TLSA : 1.1600 (+2.65%)
AIM : 0.0949 (-19.37%)
PEPG : 1.6200 (+6.58%)
AEON : 0.4050 (+1.25%)
MBRX : 1.0500 (+10.50%)
8 Small-Cap Stocks Surging Like Rockets After Game-Changing News

Small-cap stocks often deliver some of the most explosive gains when game-changing news hits the market. Investors searching for high-upside opportunities should pay attention to this week’s biggest...

RILY : 3.03 (+2.71%)
MLGO : 9.83 (-17.12%)
ENVB : 1.2300 (+3.36%)
RETO : 3.64 (+18.95%)
PEPG : 1.6200 (+6.58%)
STEC : 0.9550 (-9.91%)
ONVO : 2.0100 (+14.86%)
GDEV : 11.50 (+5.19%)
PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz?

The rally follows PepGen's release of early clinical data from its Phase 1 trial evaluating its therapy to treat a rare genetic disorder.

VXF : 162.43 (+2.71%)
IBB : 120.43 (+2.72%)
PEPG : 1.6200 (+6.58%)
IWM : 187.47 (+2.59%)
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher

Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy

SRPT : 59.31 (+7.39%)
PEPG : 1.6200 (+6.58%)
CAPR : 13.89 (+16.53%)
PepGen (NASDAQ: PEPG) Shares Phase 1 Clinical Trial Results of PGN-EDO51 Showing Positive Data in Treating Duchenne Muscular Dystrophy

PepGen, Inc. (NASDAQ: PEPG) is engaged as a clinical-stage biotechnology company, which is focused on the research and development of

PEPG : 1.6200 (+6.58%)
PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments

BOSTON, June 16, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide...

PEPG : 1.6200 (+6.58%)
It’s Time To Nibble On These Two Recent IPOs 

It’s hard to know what to buy and what to sell with market conditions the way they are but it looks like a good time to start nibbling on these two recent IPOs. Bausch + Lomb (NYSE: BLCO) and PepGen...

BLCO : 12.49 (+3.65%)
PEPG : 1.6200 (+6.58%)

Business Summary

PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 2.0867
2nd Resistance Point 1.9333
1st Resistance Point 1.7767
Last Price 1.6200
1st Support Level 1.4667
2nd Support Level 1.3133
3rd Support Level 1.1567

See More

52-Week High 19.2980
Fibonacci 61.8% 12.2624
Fibonacci 50% 10.0891
Fibonacci 38.2% 7.9157
Last Price 1.6200
52-Week Low 0.8801

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro